CA3036832A1 - Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury - Google Patents
Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury Download PDFInfo
- Publication number
- CA3036832A1 CA3036832A1 CA3036832A CA3036832A CA3036832A1 CA 3036832 A1 CA3036832 A1 CA 3036832A1 CA 3036832 A CA3036832 A CA 3036832A CA 3036832 A CA3036832 A CA 3036832A CA 3036832 A1 CA3036832 A1 CA 3036832A1
- Authority
- CA
- Canada
- Prior art keywords
- cells
- composition
- spinal cord
- subject
- cord injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394226P | 2016-09-14 | 2016-09-14 | |
| US62/394,226 | 2016-09-14 | ||
| US201762449580P | 2017-01-23 | 2017-01-23 | |
| US62/449,580 | 2017-01-23 | ||
| US201762518591P | 2017-06-12 | 2017-06-12 | |
| US62/518,591 | 2017-06-12 | ||
| PCT/US2017/051677 WO2018053210A1 (en) | 2016-09-14 | 2017-09-14 | Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3036832A1 true CA3036832A1 (en) | 2018-03-22 |
Family
ID=61620153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3036832A Pending CA3036832A1 (en) | 2016-09-14 | 2017-09-14 | Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190262405A1 (https=) |
| EP (1) | EP3518945A4 (https=) |
| JP (3) | JP2019526584A (https=) |
| CN (1) | CN109715175A (https=) |
| AU (1) | AU2017326424B2 (https=) |
| CA (1) | CA3036832A1 (https=) |
| WO (1) | WO2018053210A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL281628B2 (en) | 2018-09-19 | 2025-06-01 | Lineage Cell Therapeutics Inc | Methods for differentiating pluripotent stem cells in dynamic suspension culture |
| US20230167406A1 (en) * | 2020-05-01 | 2023-06-01 | The Children's Medical Center Corporation | Compositions and methods of promoting myelination |
| AU2022212124A1 (en) * | 2021-01-28 | 2023-08-10 | Asterias Biotherapeutics, Inc. | Compositions and methods for treating spinal cord injuries |
| IL305737A (en) * | 2021-03-10 | 2023-11-01 | Lineage Cell Therapeutics Inc | Methods for generating oligodendrocyte progenitor cells and their use |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7285415B2 (en) * | 2002-07-11 | 2007-10-23 | The Regents Of The University Of California | Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| AR046076A1 (es) * | 2003-07-18 | 2005-11-23 | Otsuka Pharma Co Ltd | Procedimiento para obtener una poblacion homogenea de celulas precursoras de oligodendrocitos y poblacion obtenida |
-
2017
- 2017-09-14 EP EP17851575.5A patent/EP3518945A4/en active Pending
- 2017-09-14 CA CA3036832A patent/CA3036832A1/en active Pending
- 2017-09-14 CN CN201780056381.7A patent/CN109715175A/zh active Pending
- 2017-09-14 US US16/333,566 patent/US20190262405A1/en active Pending
- 2017-09-14 AU AU2017326424A patent/AU2017326424B2/en active Active
- 2017-09-14 JP JP2019512280A patent/JP2019526584A/ja active Pending
- 2017-09-14 WO PCT/US2017/051677 patent/WO2018053210A1/en not_active Ceased
-
2022
- 2022-06-15 JP JP2022096318A patent/JP2022130483A/ja active Pending
-
2024
- 2024-04-04 JP JP2024061113A patent/JP2024096794A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024096794A (ja) | 2024-07-17 |
| AU2017326424A1 (en) | 2019-04-18 |
| AU2017326424B2 (en) | 2023-12-14 |
| JP2019526584A (ja) | 2019-09-19 |
| EP3518945A1 (en) | 2019-08-07 |
| WO2018053210A1 (en) | 2018-03-22 |
| US20190262405A1 (en) | 2019-08-29 |
| JP2022130483A (ja) | 2022-09-06 |
| CN109715175A (zh) | 2019-05-03 |
| EP3518945A4 (en) | 2020-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Su et al. | Lithium enhances proliferation and neuronal differentiation of neural progenitor cells in vitro and after transplantation into the adult rat spinal cord | |
| JP2024096794A (ja) | 脊髄損傷の治療のための多能性幹細胞由来オリゴデンドロサイト前駆細胞 | |
| US10545135B2 (en) | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation | |
| US20190224247A1 (en) | Methods and compositions for provision of angiogenic factors | |
| US9387226B2 (en) | Neural cell proliferation induced through the culture of neural cells with umbilical cord blood-derived mesenchymal stem cells | |
| Wang et al. | Adipose Stem Cell‐Based Clinical Strategy for Neural Regeneration: A Review of Current Opinion | |
| JP4126060B2 (ja) | 間葉系幹細胞の神経細胞への分化法と神経変性疾患用の神経細胞含有薬剤成分 | |
| US20200239853A1 (en) | Stem cell-derived sertoli-like cell, preparation method therefor, and use thereof | |
| KR20260042390A (ko) | Ptx-3, timp1 및 bdnf를 발현하는 간엽줄기세포를 유효성분으로 포함하는 염증 질환 또는 통증의 예방 또는 치료용 약학 조성물 | |
| Sivron et al. | Astrocytes play a major role in the control of neuronal proliferation in vitro | |
| WO2010030199A1 (en) | Stem cell culture | |
| KR20230007923A (ko) | 중간엽 줄기세포, 이로부터 분리된 세포외 소포체, 및 이들의 용도 | |
| KR101590722B1 (ko) | 인간 혈액 유래 혈구 세포괴를 포함하는 신경계 질환 치료용 약학적 조성물 | |
| KR20240008054A (ko) | 줄기세포 유래 엑소좀을 포함하는 항암 조성물 및 이의 제조방법 | |
| KR20150062817A (ko) | 태반의 융모막 또는 와튼제대교질 유래 간엽줄기세포로부터 신경세포 및 유모세포를 분화시키는 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220727 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240909 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240909 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240909 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250210 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250609 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250610 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250626 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250626 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251006 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251006 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260304 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20260309 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260316 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260317 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260317 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260317 |